Cooper Companies: Strong Core Demand Meets Supply and PARAGARD Risks

Transcript intelligence

What changed

Relative to the prior-quarter analysis, guidance moved from raised to maintained, capex shifted from decreasing to increasing, and the focus sharpened on MyDay capacity constraints, quarter-end U.S. and China softness, a 10% Q4 PARAGARD decline, and continued FX and competitive risks.

Guidance delta

Management maintained its FY2025 outlook, targeting 6.5–8.5% share growth in lenses, mid-single-digit organic growth in surgical, and expected margin expansion; the analysis also identifies the range as lower than expected by some analysts.

Key takeaways

• FY2024 revenue reached an all-time high of $3.9 billion, with double-digit growth in both core segments.
• MyDay daily lenses, torics, multifocals, and MiSight led contact-lens growth, while temporary U.S. and China softness weighed on the quarter.
• CooperSurgical fertility revenue grew 15%, supported by consumables, capital equipment, and advanced genetic testing.
• Capacity constraints limited MyDay supply, prompting increased capital spending to expand manufacturing lines.
• PARAGARD sales declined 10% in Q4 amid competitive pressure.

Management priorities

• Expand manufacturing capacity and improve MyDay availability.
• Broaden MyDay Energys, toric, and multifocal availability across additional markets.
• Roll out upgraded clariti multifocal lenses globally.
• Introduce additional fertility genomics tests and capital equipment.
• Integrate recent acquisitions and pursue selective M&A.